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Abstract: The association between hypoalbuminemia and
poor prognosis in patients with cancer is well recognized.
However, the factors that contribute to the fall in albumin
concentrations are not well understood. In the present study,
we examined the relationship between circulating albumin
concentrations, weight loss, the body cell mass (measured
using total body potassium), and the presence of an inflam-
matory response (measured using C-reactive protein) in
male patients (n = 40) with advanced lung or gastrointesti-
nal cancer. Albumin concentrations were significantly cor-
related with the percent ideal body weight (r = 0.390, p 
0.05), extent of reported weight loss (r = 0.492, p  0.01),
percent predicted total body potassium (adjusted for age,
height, and weight, r = 0.686, p  0.001), and log10 C-
reactive protein concentrations (r = 0.545, p  0.001). On
multiple regression analysis, the percent predicted total
body potassium and log10 C-reactive protein concentrations
accounted for 63% of the variation in albumin concentra-
tions (r2 = 0.626, p  0.001). The interrelationship between
albumin, body cell mass, and the inflammatory response is
consistent with the concept that the presence of an ongoing
inflammatory response contributes to the progressive loss of
these vital protein components of the body and the subse-
quent death of patients with advanced cancer.
Introduction
The prognostic value of hypoalbuminemia in patients with
advanced cancer has long been recognized (1,2). However,
only recently have the factors that influence its concentration
been better understood. In healthy adult men, albumin con-
centrations have been shown to correlate with lean tissue as
derived from anthropometric measurements (3). Previously,
in cancer patients it had been thought that low circulating al-
bumin concentrations were due to reduced synthesis (4) or
increased transcapillary escape rates (5). However, it has
been recently reported that the rate of albumin synthesis is
similar to that of healthy subjects in the fasted (6) and fed
state (7) and that transcapillary escape rates are within the
normal range (8). This would suggest that albumin degrada-
tion plays an important role in the hypoalbuminemia of the
cancer patient (6,7).
It is well known that, as part of the inflammatory re-
sponse to acute injury, albumin concentrations fall as those
of other acute-phase proteins, such as C-reactive protein,
rise (1). More recently, a similar inverse relationship has
been reported in advanced gastrointestinal and lung cancer
patients (9,10).
The aim of the present study was to examine the relation-
ship and interdependence between albumin concentrations,
total body potassium (adjusted for age, height, and weight),




Male patients with locally advanced or metastatic cancer
were studied. No patient had undergone surgery, radiother-
apy, or chemotherapy in the previous two months. No pa-
tient complained of moderate or severe dysphagia, and none
had obvious functional obstruction to food intake or abnor-
mal liver function tests.
Patients were questioned carefully about their weight and
any weight loss they had experienced. Age, height, and
weight were recorded together with measurement of total
body potassium. Venous blood samples were taken for rou-
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tine laboratory measurement of albumin, C-reactive protein,
and hematocrit. The study was approved by the local hospi-
tal ethical committee. All patients gave written informed
consent.
Methods
Height (to the nearest cm) and weight (to the nearest 0.1
kg) were measured using a stadiometer and beam-balance
standing scale (Weylux, Cambridge, UK). Body weight was
expressed as a percentage of the reported preillness weight
and as a percentage of the ideal body weight (defined by a
body mass index of 23 kg/m2).
Albumin concentrations were measured using the brom-
cresol green method on a Technicon RA-1000 automated
analyzer (Technicon, Tarrytown, NY).
C-reactive protein was measured by fluorescence polar-
ization immunoassay using an Abbott TDX analyzer and
Abbott reagents (Abbott Laboratories, Abbott Park, IL). The
limit of detection of the assay is a C-reactive protein concen-
tration of 5 mg/l.
Hematocrit was measured following a standard technique
on a flow cytometer (model S-Plus STKR, Coulter, Luton,
UK).
Total body potassium was determined by measuring the
amount of the naturally occurring radioisotope, 40K, in each
patient using a whole body counter (11).
The coefficient of variation for these methods, over the
range of measurement, was 5%.
Calculations
Total body potassium values were expressed as a percent-
age of predicted normal values to adjust for variations in
age, height, and weight, as previously described (11).
Data are presented as median and range. Regression anal-
ysis was performed using a linear model of patients’ albu-
min with percent ideal body weight, percent weight loss,
percent predicted total body potassium, and C-reactive pro-
tein as variables. As the distribution of C-reactive protein
concentrations was skewed, they were logarithmically trans-
formed before analysis. Concentrations of C-reactive pro-
tein below the threshold of sensitivity of the assay (5 mg/l)
were expressed as equal to this threshold.
Multivariate regression analysis was performed using a
stepwise backward procedure to derive a final model of the
variables that had a significant independent relationship
with albumin. To remove a variable from the model, the cor-
responding P value had to be 0.05.
Analysis was performed using SPSS software (SPSS,
Chicago, IL).
Results
Characteristics of the 40 male cancer patients (12 esopha-
gus, 7 stomach, 3 pancreas, 7 colon, and 11 non-small cell
lung cancer) are shown in Table 1. Thirty-seven patients had
locally advanced and three patients had metastatic disease.
The median weight loss relative to preillness weight of the
patients was 15%; this was associated with a 12% reduction
in ideal body weight. Body cell mass (as measured by total
body potassium) was significantly lower than that predicted
(p  0.001).
Albumin concentrations were significantly correlated
with percent ideal body weight (r = 0.390, p  0.05), percent
weight loss (r = 0.492, p  0.01), percent predicted total
body potassium (adjusted for age, height, and weight; r =
0.686, p  0.001; Figure 1), and log10 C-reactive protein con-
centrations (r = 0.545, p  0.001; Figure 2).
On multiple regression analysis, only the percent pre-
dicted total body potassium and log10 C-reactive protein con-
centrations remained significant at the 5% level. Together,
total body potassium and log10 C-reactive protein accounted
for 63% of the variation in albumin concentrations (r2 =
0.626, p  0.001).
Discussion
Cancer cachexia is characterized by progressive involun-
tary weight loss, loss of body cell mass, muscle weakness,
and fatigue. Although overt cachexia is clinically apparent,
minimal weight loss is frequently overlooked. In such pa-
tients, a number of nutritional indexes are recognized to pro-
vide prognostic information (12). These include albumin,
and, indeed, in cancer patients, measurements are often re-
stricted to weight and albumin. However, it is not clear what
these changes in albumin concentration reflect.
Previous studies in small numbers of patients, using
nonreference methods, suggested an association between al-
bumin concentrations and body cell mass (10,13). The pres-
ent study, using total body potassium as the reference
method, confirms that albumin concentrations correlate with
body cell mass. Furthermore, it was of interest that in the
present study there was a significant inverse correlation be-
tween circulating concentrations of albumin and C-reactive
protein, the magnitude of which was similar to that previ-
ously reported (9,13). On multiple regression analysis, body
cell mass and the systemic inflammatory response were in-
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Table 1. Characteristics of Male Cancer Patientsa
Characteristic Median (Range)
Age, yr 69 (48–76)
Height, cm 172 (158–185)
Weight, kg 60.2 (38.7–98.7)
Ideal body weight, % 87.9 (58.2–143.4)
Weight loss, % 15 (0–42)
Albumin, g/l 40 (26–46)
C-reactive protein, mg/l 18 (5–170)
Hematocrit, % 36.4 (24.5–44.5)
Total body potassium, mmol 2,330 (1,500–3,876)
Total body potassium, %predicted 86.3 (50.1–98.8)
a: n = 40.
dependently correlated with circulating albumin concentra-
tions. Indeed, when total body potassium (adjusted for body
habitus) and the inflammatory response were considered,
they accounted for ~65% of the variation in albumin concen-
tration. This paradigm gives us a better understanding of the
factors underlying hypoalbuminemia in cancer patients.
It is of interest that the inflammatory response in cancer
patients is not only associated with a reduction in circulating
albumin concentrations, probably through increased degra-
dation (6,7) but, over time, is also associated with the loss of
body cell mass (14). Therefore, it may be that the inflamma-
tory response, with its increased demand for specific amino
acids for mediator and acute-phase protein synthesis and im-
mune and antioxidant defenses (7,15,16), promotes the deg-
radation of available body protein, including albumin, and
body cell mass. The modest pool size of albumin relative to
that of body cell mass may be reflected in its loss becoming
noticeable at an earlier stage. With respect to the loss of
body cell mass, it would appear that this is primarily of skel-
etal muscle due to net skeletal muscle catabolism (17).
These changes over a prolonged period result in the nutri-
tional decline that leads to death of the cancer patient (2).
Considering the prognostic value of albumin in cancer
patients and the results of the present study, one might spec-
ulate that improving the prognosis of such patients will
require moderation of the inflammatory response and main-
tenance/restoration of body cell mass. Recent work has indi-
cated that the inflammatory response can be moderated in
the weight-losing gastrointestinal cancer patient (18,19).
However, it is not clear whether such an approach will pre-
vent the loss of body cell mass in such patients.
In this study, low albumin concentrations in male cancer
patients reflect loss of body cell mass and the presence of an
inflammatory response. The interrelationship between albu-
min, body cell mass, and the inflammatory response is con-
sistent with the concept that the presence of an ongoing
systemic inflammatory response contributes to the progres-
sive loss of these vital protein components of the body and
the subsequent death of patients with advanced cancer.
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